Synexus launches new patient registry to support longitudinal brain aging study

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/wildpixel)
(Image: Getty/wildpixel)

Related tags: Alzheimer's disease, Synexus, Ppd, Clinical trial, Clinical research, Dementia

Synexus is looking to register 30,000 adults for a five-year study with the goal of identifying potential prevention methods and possible treatments for Alzheimer’s disease and other dementias.

The Synexus HealthyMinds Registry (Synexus HMR) is being launched in collaboration with the University of Exeter in the UK.  

Synexus ​is working the patient enrollment and retention solutions provider Acurian ​to enroll 30,000 adults age 50 or older without signs of dementia. Both companies are part of Accelerated Enrollment Solutions (AES), a business unit of the contract research organization (CRO) PPD.

The initial study – which will be conducted entirely online – will examine the lifestyle and genetic risk factors affecting cognitive function.

“Research is urgently needed to identify potential methods of prevention and possible treatments for Alzheimer’s disease and other forms of dementia,”​ said Dawie Wessels, chief medical officer of Synexus.

According to the Alzheimer’s Association​, 5.7m Americans are currently living with Alzheimer’s ​– the sixth leading cause of death in the US – and by 2050, this number is projected to reach 14m.

“Synexus HMR will provide valuable information about how the brain changes with age and investigate which combination of factors such as exercise and diet really work, and how to best encourage people to adopt these changes,” ​Wessels told us.

The registry will provide participants with information about the latest advancements in dementia research and treatments, as well as “brain training games designed to help participants stay sharp,”​ he explained.

Additionally, Wessels said participants can consent to genotyping and “will be among the first to learn about clinical trials of promising new treatments for Alzheimer’s and other forms of dementia.”

“Over the next five years, registry participants will be exposed to opportunities to join clinical trials based on their cognitive assessment results,” ​he added.

Related news

Show more

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more